However, many seniors who take low-dose aspirin may not need to do this, researchers said. Nearly three in five (57%) of people ages 50 to 80 who take aspirin regularly don't have a history of ...

For years, doctors recommended that older adults at a higher risk for heart attack or stroke take a low-dose aspirin once a day to lower their risk. Aspirin helps prevent blood clots from forming ...

With daily low-dose aspirin use, risks may outweigh benefits for older adults, new research says. It's one of the most well-known tenets of modern medicine: An aspirin a day keeps the doctor away.

Taking daily low-dose aspirin was linked to an increased incidence of anemia and a decline in blood iron levels among otherwise healthy older adults, according to the results of research published ...

Research as far back as the 1950s showed a daily low dose of the anti-inflammatory ... As part of the the National Institutes of Health-funded Aspirin in Reducing Events in the Elderly ...

Older people who take a low-dose aspirin daily may be 20 percent more likely to develop anemia than those who do not, according to research published in the journal Annals of Internal Medicine.

Older people who take a low-dose aspirin daily may be 20 percent more likely to develop anemia than those who do not, according to research published in the journal Annals of Internal Medicine.

Older adults who take low-dose aspirin on a daily basis may be prone to an increased risk of brain bleeds, according to a new study. While aspirin appeared to reduce the occurrence of ...

A follow-up analysis on a National Institutes of Health-funded clinical trial found that daily aspirin use increases the risk of anemia by 20% in older adults who are otherwise healthy.

Source Reference: McQuilten ZK, et al "Effect of low-dose aspirin versus placebo on incidence of anemia in the elderly" Ann Intern Med 2023; DOI: 10.7326/M23-0675.

Use of daily low-dose aspirin for 3 years didn't prevent age-related macular degeneration (AMD) in older adults, according to a secondary analysis of the randomized ASPREE trial.